Evolocumab is a monoclonal antibody designed for the treatment of hyperlipidemia by Amgen. It is a subcutaneous injection approved by the FDA for individuals on maximum statin therapy who still require additional LDL-cholesterol lowering. It is approved for both homozygous and heterozygous familial cholesterolemia as an adjunct to other first-line therapies. Evolocumab is a human IgG2 monoclonal antibody that targets the proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that targets LDL receptors for degradation, therefore reducing the liver's ability to remove LDL-cholesterol (LDL-C), or "bad" cholesterol, from the blood. Evolocumab is designed to bind to PCSK9 and inhibit PCSK9 from binding to LDL receptors on the liver surface, resulting in more LDL receptors on the surface of the liver to remove LDL-C from the blood. Evolocumab is the second PCSK9 inhibitor on the market, first being alirocumab.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Evolocumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Evolocumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Evolocumab. |
| Estrone | Estrone may increase the thrombogenic activities of Evolocumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Evolocumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Evolocumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Evolocumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Evolocumab. |
| Estriol | Estriol may increase the thrombogenic activities of Evolocumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Evolocumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Evolocumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Evolocumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Evolocumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Evolocumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Evolocumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Evolocumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Evolocumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Evolocumab. |
| Equol | Equol may increase the thrombogenic activities of Evolocumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Evolocumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Evolocumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Evolocumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Evolocumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Evolocumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Evolocumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Evolocumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Evolocumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Evolocumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Evolocumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Evolocumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Evolocumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Evolocumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Evolocumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Evolocumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Evolocumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Evolocumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Evolocumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Evolocumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Evolocumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Evolocumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Evolocumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Evolocumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Evolocumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Evolocumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Evolocumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Evolocumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Evolocumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Evolocumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Evolocumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Evolocumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Evolocumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Evolocumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Evolocumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Evolocumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Evolocumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Evolocumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Evolocumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Evolocumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Evolocumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Evolocumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Evolocumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Evolocumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Evolocumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Evolocumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Evolocumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Evolocumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Evolocumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Evolocumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Evolocumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Evolocumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Evolocumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Evolocumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Evolocumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Evolocumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Evolocumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Evolocumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Evolocumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Evolocumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Evolocumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Evolocumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Evolocumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Evolocumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Evolocumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Evolocumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Evolocumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Evolocumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Evolocumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Evolocumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Evolocumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Evolocumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Evolocumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Evolocumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Evolocumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Evolocumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Evolocumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Evolocumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Evolocumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Evolocumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Evolocumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Evolocumab. |